Praise for The Definitive Testosterone Replacement MANual

"Inspiring is Jay's knowledge of hormone replacement and human physiology, which surpasses that of many of my medical colleagues. This he brings to you the reader in the pages of his much-needed and timely opus. Open your eyes, read and digest Jay's words. This book is the chapter that I was scared to write."

Brett Osborn, MD Diplomate, American Board of Neurological Surgery Diplomate, American Academy of Anti-Aging Medicine CSCS, National Strength and Conditioning Association, Author of Get Serious, A Neurosurgeon's Guide To Optimal Health and Fitness

"The Definitive Testosterone Replacement MANual presents practical information about the best ways to maximize benefits and minimize side effects of testosterone replacement therapy. It accomplishes this goal in the most visually appealing way I have ever seen in this field. This book makes for an enjoyable and highly empowering read for any man who wants to take charge of his health and quality of life."

Nelson Vergel CEO, ExcelMale.com and DiscountedLabs.com, Author of Testosterone A Man's Guide: Practical Tips For Boosting Physical, Mental and Sexual Vitality

Is your sex drive at its peak, or has it diminished? Is your enthusiasm for life lessening?

Healthy testosterone levels are not only a physical state of prime health, but a mental state of positive wellness and aggression.

A man with low testosterone will experience not only a physical decline, but also a diminished quality of life.

Testosterone is often misrepresented by the media at large as inciting "hostility", or its effects are reduced down to building muscle only, and its portrayed as being detrimental to health. Nothing could be further from the truth. Comprehensive clinical evidence has unequivocally demonstrated that healthy testosterone levels not only slow the aging process and improve physical markers of health, but that they also reduce the possibility of degenerative disease, and by extension vastly improve quality of life.

Men NEED Optimal Testosterone Levels to age powerfully and live to their maximum potential.

The Definitive Testosterone Replacement Therapy MANual is the first book of its kind covering not only the therapeutic practice and application of TRT, but the historical, sociological, and biological issues that inform its usage.

The rest is here:
The Definitive Testosterone Replacement Therapy MANual ...

The first thing to understand about testosterone replacement is that oral testosterone (pills taken by mouth) doesnt really work because it is broken down so quickly by the liver. The solution to this problem involves patches, gels, shots, and even nasal sprays. Here are your options, with some new players in the game.

Androderm patches are meant to be worn on the arm or torso. Androderm patches deliver approximately 5 mg of testosterone per 24 hours and result in normal testosterone levels in the majority of hypogonadal men. These have been around for a while.

Four testosterone gels are available: AndroGel, Testim, Fortesta, and Axiron.

The option of intramuscular injections is a good one, though it requires office visits. Injections are usually given one shot of 100 mg, once a week for 12 weeks. Regimens of 300 mg every three weeks and 400 mg every four weeks can also be used. An advantage of the shots for men is the freedom from daily administration of a gel or patch, while the disadvantages are the need for a shot of an oily solution every one to three weeks.

Natestois the first nasaltestosteronegel approved in the United States for the treatment of male hypogonadism andtestosteronedeficiency.Natestois a metered-dose pump applicator that places the gel into the nostrils.

The good thing?Because this gel is applied inside of the nostril, there is little chance of transferringtestosteroneto women or children who come into close physical contact with the person using the intranasal gel. That can occur with the gels and patches used on the skin.

There are some disadvantages.Some men wont like that it needs to be used three times daily. People with allergies or underlying nasal or sinus problems also may not likeNatestoas a runny nose, sore throatand sinusitis are among the most common side effects.

Thoughts?

Dr. O.

Most options for testosterone replacement are considered Tier 2 drugs by many insurance plans, though they may fall under higher copays or may not be covered with some plans. Androderm patches and all gel options run about $550-$600 per month or per prescription (for 30 patches or one container of gel). Testosterone shots are significantly less expensive, with generic versions sometimes available for as little as $20 per dose.

See the original post:
Testosterone Replacement: Options for Treatment Have ...

Dear Dr. Roach I am a 67-year-old male in fair to good health (more good than fair, really). In a recent column, you mentioned that a good testosterone level for a man taking a replacement would be between 500-600 ng/dl.

In November 2016, I was tested for my testosterone level. At the time, I was (and still am) suffering from a low sex drive and erectile dysfunction. My level was 290 ng/dl. The reference range my primary care doctor bases his judgment on has an acceptable range from 193-950 ng/dl; hence he said my level was low normal.

When looking at the symptoms of low testosterone, I noted that I have at least four symptoms: low sex drive, ED (for which I have already been treated with a prosthetic implant), loss of body hair (especially my legs) and, most notably, osteoporosis (for which I take alendronate sodium, 70 mg weekly). I was diagnosed in November.

I also am being treated for depression and anxiety disorder, and have been since 2001. I dont know if this is related to my testosterone level.

Should I talk to my doctor about the disparity Ive found in reference ranges? Should I be seeking treatment for the low testosterone? J.P.P.

Answer I think you definitely should speak to your primary care physician. You also might benefit from a discussion with a urologist or endocrinologist with experience in treating men with testosterone replacement.

When we look at normal testosterone levels by age, we find that older men have lower normal levels; however, given your symptoms and result, I certainly would think a trial of testosterone would be appropriate. I must say that I am surprised that you had an implant placed without a trial of testosterone first. I also am surprised you were treated for osteoporosis without a trial of testosterone replacement, which has been shown to improve bone density in men with low testosterone levels (one study treated men with a testosterone level below 350; another if they were below 320). Low libido and erectile dysfunction both frequently respond to testosterone replacement: Some men get benefit in their mood as well. You sound to me like an excellent candidate for testosterone replacement.

Dr. Roach regrets that he is unable to answer individual letters, but will incorporate them in the column whenever possible. Readers may email questions to ToYourGoodHealth@med.cornell.edu or request an order form of available health newsletters at 628 Virginia Drive, Orlando, Fla. 32803. Health newsletters may be ordered from rbmamall.com.

See original here:
Testosterone replacement can affect sex drive, osteoporosis | To ... - STLtoday.com

MY EPIC FAIL + I NEED QUESTIONS for New Q A Series! (Please Thx!)
With life still being unpacked and lots to do during my days off I thought it best get some fresh questions for a new Q A on the channel. All topics are great including Testosterone Replacement...

By: bignoknow

Follow this link:
MY EPIC FAIL + I NEED QUESTIONS for New Q&A Series! (Please & Thx!) - Video

what is testosterone replacement therapy | Find what is testosterone replacement therapy
what is testosterone replacement therapy | Find what is testosterone replacement therapy Testosterone Replacement Therapy as well as Advantages Simply by des...

By: what is testosterone replacement therapy

The rest is here:
what is testosterone replacement therapy | Find what is testosterone replacement therapy - Video

TRT - Week 9 (Testosterone Replacement Therapy)
Wanna know why I am on Testosterone Replacement Therapy? https://www.youtube.com/watch?v=9zRpjjGdMgQ Follow me on Twitter: https://twitter.com/TheTRTBrah and Facebook: https://www.faceb.

By: TRT Brah

Go here to see the original:
TRT - Week 9 (Testosterone Replacement Therapy) - Video

Prostate Cancer and Testosterone Replacement

By: BioBalanceHealthcast

Continue reading here:
Prostate Cancer and Testosterone Replacement - Video

Episode 13 Why I #39;m Pro Testosterone Replacement
I have been testing both men and women for low levels of testosterone for at least 15 years. The incidence of low T is, quite frankly, astounding. I have my ...

By: The Dr. Fred Show

Link:
Episode 13 Why I'm Pro Testosterone Replacement - Video

Miami Testosterone Replacement Therapy Clinics
Miami Testosterone Replacement Therapy Clinics Men with low testosterone had a 33 percent greater death risk over their next 18 years of life compared with men who had higher testosterone,...

By: Miami Testosterone Replacement Therapy Clinics

Read the original:
Miami Testosterone Replacement Therapy Clinics - Video

Denver Testosterone Replacement Clinics
Watch this video to uncover two testosterone therapy clinics in Denver that offer multiple services for Men. You will also learn what the four most commonly ...

By: Anti-Aging For Men

Excerpt from:
Denver Testosterone Replacement Clinics - Video

Testosterone is a major sex hormone produced in the testes of men. The pituitary gland is responsible for controlling the production of testosterone hormone. In the testes, luteinizing hormone binds to receptors on Leydig cells; this stimulates production and secretion of testosterone. Testosterone helps to develop the primary and secondary sexual characteristics in males. Development of sex organs, deeper voice, muscle mass, and facial hair all result from the sufficient production of this hormone. Testosterone deficiency as happens with age needs effective testosterone treatment.

Along with the development of sexual features, testosterone hormone also controls the following actions in a body:

With age, testosterone production declines, thus disturbing overall body functioning. Low levels of testosterone hormone lead to a condition termed as hypogonadism that can be treated with testosterone replacement therapy. Hypogonadism can be divided into two categories depending on the occurrence of pathology.

Primary Hypogonadism: It occurs at testicular level with high release of follicle stimulating hormone (FSH), luteinizing hormone (LH), and low release of testosterone.

Secondary Hypogonadism: It occurs at pituitary hypothalamic level with low or in some cases normal release of luteinizing hormone and follicle stimulating hormone along with low levels of testosterone hormone.

Testosterone replacement therapy effectively works to improve upon the conditions of primary and secondary hypogonadism.

Along with aging, there are some other factors that contribute toward low testosterone production and make a man go for testosterone treatment.

Deficient testosterone hormone levels can lead to many undesirable symptoms, like poor libido, lack of vitality, erectile dysfunction, declining muscle mass, osteoporosis, loss of body hair, depression, lower blood hemoglobin, memory loss, poor concentration, mood swings, mild anemia, disturbed cholesterol profile and a decrease in cognitive function that effects all of your activities. Testosterone therapy is the only possible way to cope with testosterone deficiency.

Before start of the testosterone treatment, there should be the right detection of the hormone deficiency. If you consult an expert doctor for testosterone therapy, he may prescribe you the blood test in the morning because testosterone levels are at peak during that time.

We, at Nationwide Synergy Inc, provide patients with best available options to treat their hormone deficiency.

Continued here:

Testosterone Replacement Therapy - Testosterone Treatment

Testosterone Replacement Drugs | Testosterone Replacement Side Effects | Testosterone Lawsuit
Testosterone Replacement Drugs | Testosterone Replacement Side Effects | Testosterone Lawsuit The following conversations are provided aid clear up many of t...

By: Testosterone Lawsuit

More here:

Testosterone Replacement Drugs | Testosterone Replacement Side Effects | Testosterone Lawsuit - Video

Low Testosterone Claims: Options in a Growing Class Action Suit
Millions of men accross the country are experiencing health issues related to the use of testosterone replacement therapy drugs. A recent statement from the FDA has labeled these drugs as potential...

By: Aronfeld Law Firm

See the rest here:
Low Testosterone Claims: Options in a Growing Class Action Suit - Video

Image Source: Health Journals

Antares Pharmaceuticals' (ATRS) XYOSTED may be one of the best testosterone therapies available when evaluated against competitors such as Aveed, Depo-Testosterone, Delatestryl, and Testopel. Considering the sector has decade-old generics priced at $25/mo., management should be praised for its efforts to grow XYOSTED scripts to over 7,000/mo., and its revenues by 100% Y/Y despite a $550/unit pricing. Overall, this results in the company trading for merely 2.5x FY 2020 EV/Sales in terms of valuation, making the stock a strong buy.

In its earnings report early November, ATRS saw its bottom line improve by 182% Y/Y and posted a profit of $0.01 per share. Its annual guidance increased by 10% to $115 million for FY 2019. Revenues were also up sharply, growing by over 100% Y/Y with 46.5% of its growth coming from the launch of XYOSTED (subcutaneous testosterone enanthate injection) indicated for testosterone replacement therapy in hypogonadal men.

Source: Bloomberg Terminal/Symphony HealthCare Solutions

Much of this organic growth can be directly attributed to XYOSTED's prescription count. Based on data from 2 leading competitors, TRX for TRT grew nearly 200% YTD. Nearly 58% of this increase can be attributed to XYOSTED, which saw its prescription count balloon to over 7,000 units/mo.

The drug is currently priced at ~$550/unit retail, and is largely in-line with ATRS's revenue figures when multiplied by monthly prescription count. Whilst a simple calculation, this is fantastic news for ATRS as a drug's list price is usually at a premium to its net price due to bulk discounts and negotiations with pharmacy benefit managers. A lack of pricing differential in the case of XYOSTED indicates and reiterates its significant value proposition for patients.

Currently, XYOSTED's major competitors in the TRT market include Aveed, Depo-Testosterone, Delatestryl, and Testopel. Each and every single one of these drugs possesses disadvantages which puts XYOSTED in the spotlight when competing against sector players.

For starters, 90% of hypogonadal patients taking XYOSTED saw their testosterone levels return to normal (300 to 1100 ng/dl) after 12 weeks. There were no abuse-related adverse events reported in its clinical trials, as no single patient had witnessed testosterone levels spike beyond 1500 ng/dl. Furthermore, while its label indicates XYOSTED may be linked to major adverse cardiovascular events, medical literature have debunked this hypothesis. While the FDA has cited 4 studies suggesting an increased risk of heart disease post TRT, over 100 studies have reported reduced CV risk with higher endogenous testosterone concentration.

All combined, this gives XYOSTED a definitive advantage against standard TRT, some of which are decades old and cost just $25 per month retail. One such competitor is Delatestryl, which only has a minimum efficacy of 72% in normalizing testosterone levels and is suffering from supply shortages.

Another generic, Testopel, is not performing so well either. The drug was approved in 1972, but saw various hurdles related to its pharmaceutical parameters and was not marketed until 2008. In follow-up studies, 100% of patients who took the drug saw their testosterone levels normalize after 4 weeks, but this metric dropped to just 31.8% after 16 weeks of treatment.

As for Aveed and Depo-Testosterone, these are currently the most prominent competitors to XYOSTED. However, even these drugs have their fair share of drawbacks. Patients taking Aveed and Depo-Testosterone have reported severe fluctuations in mood/libido, and serious risks of anaphylaxis respectively.

As shareholders should see, XYOSTED possesses one of the best clinical profiles out of all sector players. It's superb efficacy, low prevalence of serious adverse events, and negligible risks of abuse makes it a leading candidate in a total addressable market estimated to be worth $2.2 billion in FY2018.

On the other hand, there continues to be over 10 new cases of testosterone deficiency per 1000 persons per annum. It is now estimated 2.1% to 12.8% of middle aged men have this condition. As a result, the CAGR of the total addressable market for its treatment isn't likely to decline any time soon.

With an annual run rate of $46 million in XYOSTED revenues, the drug has captured approximately 2.1% of the TRT TAM 1 year after launch, and is growing at +100% annually. In a past article, the author was critical of management for paying themselves nearly $6.4 million in annual share-based compensation and salaries while revenues stagnated at the $40 million mark. However, ATRS's leadership should now be applauded for their ability to grow sales of XYOSTED in a hypercompetitive market filled with generic competition.

Currently, the company has an enterprise value of ~$600 million and possesses negligible debt. While the company is expensive in terms of backward-looking metrics, the future is rather bright for ATRS. In terms of valuation, the company is trading at 10x EV/TTM Sales, but is only priced at 5x FY 2019 EV/Sales, and is valued as little as 2.5x FY 2020 EV/Sales. 10x spot revenues is not an expensive premium to pay for a company growing its sales at 100%. Hence, Investors interested in small-cap biotech should consider ATRS as an enticing growth stock.

Disclosure: I am/we are long ATRS. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Read more here:
Antares' Xyosted Is One Of The Best Testosterone Replacement Therapies Available - Seeking Alpha

Reclaim Your Energy and Sex Drive Reclaim Your Youthful Energy and Sex Drive!

Low testosterone levels commonly known as Low T, Hypogonadism & Andropause . . . find a doctor. The condition can produce devastating symptoms that include dramatically reduced sex drive, weight gain and a loss of energy and enthusiasm just to name a few.

Just because lower testosterone is associated with natural aging doesnt mean you have to accept a lower quality of life. To reduce or even eliminate the debilitating symptoms of Low T, Dr. Lionel Bissoon evaluates and treats the condition in both men and women.

Although low levels of testosterone are often associated with older men, testosterone levels begin naturally declining at about age 30. It should come as no surprise, therefore, that even younger people can be candidates for testosterone replacement therapy.

One of the first symptoms of lower testosterone is a decrease in libido. Reduced sex drive is a sign that there isnt enough testosterone present in the circulating blood. Unfortunately, patients with decreased libido and other Low T symptoms are often told by physicians that their testosterone falls within normal levels for their age group, and are sometimes denied testosterone replacement treatment.

Theres just one problem with this diagnosis: the difference between high and low normal is significant. Because of this, many men experience low-testosterone symptoms when their testosterone level falls below 50% of the median range for their age group.

Dr. Bissoons approach is to evaluate patients symptoms as well as their blood test results to determine who will benefit from testosterone replacement therapy. In other words, Dr. Bissoon listens to his patients to ensure they live healthier, happier lives.

Testosterone replacement treatment can produce transformative results, assuming there are no other underlying medical problems. Thus, Dr. Bissoon will perform a complete medical evaluation to assess your testosterone (and other hormone) levels.

Continue reading here:

Reclaim Your Energy and Sex Drive | Testosterone ...

benefits of testosterone therapy , testosterone replacement therapy , testosterone therapy
http://www.lnk123.com/SHLu0 Pro Testosterone is backed by proven herbal science with research to back it up. This has combined to create a completely natural supplement than can help...

By: Vale Elaw

View post:
benefits of testosterone therapy , testosterone replacement therapy , testosterone therapy - Video

Both Aytu BioScience (AYTUD) and Lipocine Inc. (NASDAQ:LPCN) are advancing novel testosterone replacement therapies, but when placed side by side, which stock may make investors pumped for joy?

The testosterone replacement therapy market is a hot sector with companies focused on grabbing as much of the estimated $2 billion market as they can. Two emerging companies, in particular, are focused on delivering shareholders both near- and long-term value propositions by advancing their unique TRT products, one of which has recently hit the market. While several large pharmaceuticals are well entrenched in the TRT market already, their products, like AbbVie's (NYSE:ABBV) AndroGel, Eli Lilly's (NYSE:LLY) Axiron and Endo International's (NASDAQ:ENDP) Fortesta, are plagued with the most severe of Food and Drug Administration (FDA) warnings the dreaded Black Box warning. Thus, with the market opportunity open to treatments that may provide a better solution without the known risks of currently marketed TRT products, let's place two peer competitors side by side to determine the chances of either taking a bite out of the current market potential.

Is Aytu BioScience the 'wise choice?'

Although Aytu BioScience experienced a tough month in August, likely attributable to the recent capital raise, the company has never been stronger from a clinical and marketing perspective. Now that the split is old news and with shares trading above $3.70, the distractions of the past month may soon get replaced with investor optimism about the company's lead TRT product, Natesto.

Natesto has the potential to become a game changer in the TRT market. Although Aytu is marketing with a much smaller budget than those with already approved therapies on the market, at some point investors believe that wisdom will soon replace big pharma muscle, making Natesto the TRT of choice for prescribing physicians. And, when looking at published clinical data, the case for a market-leading Natesto should not be cast off as pure fodder. In fact, when comparing Natesto to Lipocine's pipeline TRT, Tlando, as well as to a host of other big-name drugs, Natesto has demonstrated statistically better efficacy and appears to be a safer and more effective treatment than most TRT products currently on the market.

Keeping the focus only on both companies' TRT products, other promising Aytu pipeline products won't get considered. Investors should not discount the value inherent to the Aytu pipeline consisting of a male infertility product MiOXSYS and a female sexual wellness product Fiera that like Natesto may offer significant and compelling market advantages. OK, so what about Natesto's bid to be best in class?

First off, Natesto is the only nasally administered TRT on the market. And, while some investors may not understand the significance of that issue, users of the product will. Being nasally administered helps to alleviate inadvertent transfer of testosterone, provides consistent and efficient dosing and offers significant convenience over topically applied products. Because of these advantages, Natesto is the only currently marketed FDA-approved topical TRT product not labeled with the severe FDA-required Black Box warning. Those safety and convenience issues are just the tip of the iceberg in the advantages column; there is more to Natesto to justify its place in the $2 billion TRT market.

It's no accident that Natesto has been called the potential best-in-class therapy on the market. Coming off its recent spike of over 300% in new prescription volume, Natesto is grabbing the attention of physicians due to the proven effectiveness of the product, which also leaves behind the severe side effects for patients. The differentiating factors are apparent; Natesto reduces or eliminates the potential for accidental transfer and does not require a man taking the product to quarantine himself from a female or child while the product is applied.

Additionally, being a hands-free application, Natesto offers consistent dosing in a measured treatment, and that's an important issue since excessive intake of testosterone is not necessarily a good thing for patients. Of perhaps greater importance, though, is that Natesto does not significantly reduce levels of LH and FSH hormones in the body, which has caused side effects in patients (including reducing sperm count and decreasing testicle size) who use products like AndroGel, Axiron, Fortesta and injectable products. Not only does Natesto maintain proper hormone levels in patients, but it also eliminates the potential for users getting hooked on testosterone treatments to maintain healthy testosterone levels. Natesto excels in other areas of concern as well, demonstrating a better safety profile over long-acting gels and injections that have been shown to increase hematocrit concentrations in the patient. That is, the treatments make the patient's blood thicker, which may lead to stroke and cardiac-related complications in patients. From a safety perspective, Natesto is best in class, but what about the efficacy?

The safety profile is significant, but it's how Natesto performs that is the real story. Marketed as "testosterone in seconds," Natesto is now the first and only FDA-approved intranasal TRT on the market. In a clinical trial, the majority of patients achieved statistically significant improvement in each of the five domains of erectile function. In most cases, the effect on normalizing erectile function occurred within the first 30 days of treatment. In addition to the benefits mentioned, 70% of men in the Natesto pivotal trial said they would switch from their current TRT to treatment with Natesto. Thus, no surprise that Natesto has seen a sharp trend higher in new prescription rates, with new authorizations for the product doubling since May. Also, 90% of men taking Natesto get their testosterone levels back to "normal," which is higher than other TRTs. And most men taking Natesto see their moods improve as soon as 30 days from starting treatment. The market is estimated to stand at approximately $2 billion currently, and if Aytu maintains the current trend, even a 10% market penetration can return over $200 million in new revenues.

Now that Aytu has roughly only 4 million shares outstanding, a revenue spike of that magnitude would most likely cause a disproportionate rise in company market cap, which currently reflects anemic value considering this potentially game-changing product. Adding in the potential of Aytu's other marketed products, the company may be a very wise choice for investors seeking long-term value and probability for share price appreciation.

Is Lipocine the 'wise choice?'

Lipocince is developing a testosterone product called Tlando. Although the product is not yet on the market, Lipocine is the closest peer to Aytu from a market perspective. Lipocine is taking a different approach for Tlando, testing an orally administered dose of testosterone, which the company plans to submit to the FDA for approval in the coming months. Investors need to know that the FDA has already denied the application for Tlando once, but Lipocine is preparing to try for approval once again, relying on similar data from the original rejected application.

A potential drawback for the oral administration of Tlando is that patients will be required to keep a consistent diet, maintaining certain fat content and calorie intake. And this is the case for each dosing. If patients fail to adhere to specific dietary requirements, patients are unlikely to see a meaningful rise in testosterone levels, which would be a huge problem and a potential marketing nightmare for the product. A significantly more adverse scenario is that during the company's FDA studies, a handful of men reached testosterone levels of over 2500 ng/dl, which is both extremely high and dangerous.

In addition to potential FDA problems looming for Tlando, the company itself said in a press release that LPCN 1021 (Tlando) only "generally met" the prespecified per dose secondary endpoints for twice daily oral administration. In layman's terms, the product either meets the endpoint or it doesn't, and when the company itself publishes mixed messages, investors should pay close attention. Also important to note is that the FDA will be highly unappeased if men being treated by Tlando exceed the 2500 ng/dl level, making the chances for approval unlikely. And to add insult to potential misery, as far as the FDA is concerned, when endpoints are "generally met," product support is unlikely. The FDA's words, not mine.

The biggest issue for Tlando compared to Natesto, though, is that when placed side by side, Tlando does not get as many men to normal testosterone levels. Company-sponsored studies demonstrate a significant edge in benefit from Natesto with 90% of males reaching normal testosterone levels, compared to just 70% of patients reaching normal testosterone levels when using Tlando. The FDA has made it known that at least 75% of men taking the testosterone product must reach normal T levels so it is difficult to understand how the FDA would even approve Tlando. Additionally, with Tlando known to produce dangerously high testosterone concentrations in some men, the road to approval may be far tougher than even the most optimistic investor may be willing to admit.

The 'wisest choice?'

Comparing the two, Aytu emerges as a clear "wise choice" for investors wanting exposure to the multibillion-dollar TRT market. Interestingly, Lipocine has a current market cap of roughly $75 million compared to Aytu's approximately $15 million market cap. From both a product and valuation standpoint, the opportunity for growth is substantial in the Aytu BioScience camp, particularly when you consider that there is no regulatory risk for Aytu. The product is already on the market and growing rapidly. Although a slim chance exists for approval for Tlando, the product would most likely be met with considerable marketing difficulties. Conversely, with Aytu's Natesto already approved and marketed, the promise again lay squarely in the Aytu potential.

Now that the TRT comparisons are noted, it's fair to factor in both Aytu's and Lipocine's additional pipeline opportunities. While a slight opportunity may have existed for Lipocine to present itself in a better light, the company is yet to produce an impressive clinical statistic. Thus, the clear advantages still weigh heavily in Aytu's favor, solidifying its position as the better of the two. With a pipeline focused on making use of a combined market opportunity of more than $11 million in the bank following its recent capital raise, in this case, Aytu BioScience is the superior choice for investors looking to "choose wisely."

This article was originally featured on CNA Finance.

Disclosure: The author has no positions in any stock mentioned in this article.

Visit link:
Choosing Wisely: Aytu BioScience vs. Lipocine - GuruFocus.com - GuruFocus.com

2018 saw a plethora of reports on testosterone replacement therapy, health risks, studies, trials, and types of TRT. Here at HGH doctor, our hormone replacement physicians keep up on the latest research to ensure we provide the best quality care to our clients. Part of our focus is passing new information and studies forward to you here on our website.

The results of one study on middle-aged and older men focused on the best type of treatment for fat-free mass (FFM) and muscle strength response. Men participating in the study received either intramuscular testosterone injections, transdermal TRT, or a placebo.

Although all forms of testosterone therapy showed positive improvements in FFM, total body strength, and lower and upper extremity strength, the changes seen were 3 to 5 times greater in the men who received testosterone injections rather than transdermal TRT. [1]

Testosterone therapy studies such as this one help our doctors choose the appropriate treatment for each person.

The Testosterone Therapy Trials in elderly men consisted of seven coordinated trials looking at the following areas:

We will report on these, as well as other trials and studies in this article.

Testosterone studies shed light on the benefits and safety of using testosterone replacement therapy.

For years, doctors steered men with or at greater risk of developing prostate cancer away from TRT. Even if a male had all the signs of low testosterone, many doctors believed that treatment with testosterone therapy would increase prostate cancer dangers. Luckily, there has been much research done in this area, showing the safety and benefits of TRT following prostate cancer treatment. Also, men who suffer from prostate enlargement or prostate cancer risks can also safely use testosterone therapy.

In the most recent testosterone replacement therapy studies, mounting evidence points to the safety of testosterone without reducing the risk of prostate cancer.

In a pooled analysis of 18 testosterone replacement therapy recent studies on 3,886 men diagnosed with prostate cancer, and 6,439 in the control group, there was no association between testosterone levels, DHT, and prostate cancer. [2, 3]

In a 2017 report, the Registry of Hypogonadism in Men reported that there was no increase in the odds of developing prostate cancer with the use of TRT. [4]

A 2013 study of men who underwent prostatectomy for prostate cancer found no increased risk of prostate cancer following testosterone therapy. [5]

In 2015, a study of men who underwent radiation therapy for prostate cancer followed up by testosterone therapy showed only a minor increase in serum PSA and a low rate of biochemical recurrence. [6]

Based on the current research, testosterone replacement therapy shows positive benefits for improving quality of life and well-being in men treated for prostate cancer.

With a multitude of testosterone replacement therapy studies reversing the prior concerns about cardiovascular risk, many men can improve their quality of life with TRT to treat the symptoms of hypogonadism.

Testosterone supports heart health through the production of red blood cells needed for circulation. Additionally, testosterone improves nitric oxide production crucial for proper insulin function and blood flow.

Nitric oxide is crucial to heart health and is made by the endothelium the lining of the blood vessels. Testosterone helps to lower LDL cholesterol to reduce the plaque clogging the arteries.

In 2017, a look at testosterone and the heart showed that low levels of testosterone might increase risk factors for metabolic syndrome, coronary artery disease (CAD), and type 2 diabetes. Testosterone replacement therapy helps to improve myocardial ischemia in males diagnosed with CAD. TRT also increases exercise capacity in men with congestive heart failure (CHF). Testosterone aids in weight loss and improving serum glucose levels and insulin resistance. This study reports that TRT reduces the risk of mortality in testosterone deficient men. [8]

Testosterone has many benefits for heart health, improving circulation, and reducing the risk of cardiovascular disease.

The study duration of one year consisted of receiving either testosterone gel or a placebo. Three different questionnaires every three months assessed sexual function. Results of the study showed that TRT had significant improvements for 10 out of 12 measures of sexual activity. [9, 10]

Testosterone replacement therapy studies for men with urinary symptoms such as urinary frequency, weak stream, urgency, straining to void, and other issues have found that benign prostatic hyperplasia (BPH) can impact urinary health. Prostate enlargement often occurs as men age, along with a decline in testosterone levels. Urinary issues can impact not only quality of life, but also overall health. Treatment with testosterone therapy has been shown to decrease nocturia (nighttime voiding) and improve urinary symptoms. [11]

A 2017 study of more than 650 men showed that testosterone therapy reduces weak urinary stream, nighttime waking to urinate, incomplete emptying of the bladder, and frequent urination. Additional benefits were found in erectile functions and quality of life. [12]

Testosterone has benefits for improved sexual functions as well as urinary health.

Reviewing testosterone replacement therapy studies allows our doctors to incorporate the latest research into patient treatment protocols. Low testosterone is frequently associated with the following medical conditions:

In the Physical Function Trial for men with hypogonadism, the focus was on walking distance as a measurement of testosterone benefits. TRT increased the fraction of distance walked, and the absolute increase in distance walked in 6 minutes.[13]

The Vitality Trial measured only the Functional Assessment of Chronic Illness Therapy fatigue scale, and while the results were not significant, the overall findings from the entire testosterone trials whose positive improvements on vitality, mood, and depression symptoms. However, a 2018 report found that testosterone replacement therapy reduces depressive symptoms except in individuals with major depressive disorder.[14]

The results of the Anemia Trials from these studies on testosterone therapy were extremely positive. In both men with explained and unexplained anemia, there was a considerable increase in hemoglobin concentration. The increase was associated with a significant change in the impression of vitality and general health in these men.

The Bone Trial purpose was to determine if TRT in older men could increase volumetric bone mineral density (vBMD) and bone strength. The outcome showed a total increase in vBMD of the trabecular bone in the spine as well as the whole bone vBMD. Hip strength also improved with TRT. Treatment with testosterone therapy could result in reduced risk of bone fractures for older men.

A surprising outcome of the Testosterone Therapy Trials is that there was not much in the way of cognitive benefits. However, other studies offer different findings. A double-blind, placebo-controlled study found modest improvement in global cognition.[15]

Testosterone replacement therapy can benefit physical ability, red blood cell production, and bone density.

Based on the many testosterone replacement therapy studies available for review today, we believe that the safe and supervised use of TRT can offer many benefits for middle-aged and older men. The key factor here is the need to engage in proper diagnostic testing for low testosterone and remain under doctor-supervision while receiving testosterone therapy.

To date, there is less research on testosterone therapy for women with Low T. A 2014 review of 20 randomized, placebo-controlled trials shows positive benefits for sexual response, sexual desire, frequency of activity, and overall satisfaction and orgasm. The majority of research does not show a connection between testosterone and breast cancer, making TRT a possible menopausal treatment for women who cannot use estrogen therapy. [16]

A 2015 report discusses the possible cardiovascular effects of testosterone for women, as well as enhancements for cognitive performance and musculoskeletal health in postmenopausal women. [17]

Regarding future testosterone therapy studies, 2019 should also be a promising year. HGH Doctor looks forward to keeping you informed of the latest research. At this time, we believe testosterone therapy to be extremely safe for men and women following proper diagnostic procedures.

For more information on testosterone replacement therapy, please contact our hormone clinic for a free and confidential consultation.

Research has shown testosterone replacement therapy to be extremely safe and highly effective for treating symptoms of Low T.

More:
Testosterone Replacement Therapy Studies 2019

Global Testosterone Replacement Therapy Market 2019 report provides by Market Research Store is the representation of the testosterone replacement therapy Market area through research, development, and analysis of information from multiple sources. The Global testosterone replacement therapy report bifurcates the testosterone replacement therapy Market based on various parameters, including the nature of products and services, technology development and end-user applications for a better understanding of analytical data.

In the Testosterone Replacement Therapy Market 2019 research report professionals describe the different facets of the industry with a specific goal after assessing the key factors that could manipulate the development of the testosterone replacement therapy Industry sector. This article focuses on testosterone replacement therapy quantity and value at a global level, local level, and company level. From a global prospect, this report illustrates the overall testosterone replacement therapy market size by analyzing historical data and future forecasts. The Competitive landscape mapping the trends and outlook of the report which highlights a clear insight about the market share analysis of major industry players including AbbVie,Endo International,Eli lilly,Pfizer,Actavis (Allergan),Bayer,Novartis,Teva,Mylan,Upsher-Smith,Ferring Pharmaceuticals,Kyowa Kirin,Acerus Pharmaceuticals.

Get Sample For Technological Breakthroughs (Use official eMail ID to Get Higher Priority) at:https://market.us/report/testosterone-replacement-therapy-market/request-sample

Competitive Analysis

One of the most important sections of this report is competitive analysis and this why the team of experts in testosterone replacement therapy has left no stone unturned while investigating the global testosterone replacement therapy market. The precise section provides detail information about the overview of the company, product overview, and key developments associated with the precise company.

The most fundamental feature of this report is the inclusion of the SWOT analysis of key companies. SWOT analysis is helpful in giving information about threats and opportunities and weaknesses and strengths, which are faced by companies operating in the global Testosterone Replacement Therapy market.

To Get Instant Access, Purchase Report Here:https://market.us/purchase-report/?report_id=18112

Top growing factors by Key Companies like:

AbbVieEndo InternationalEli lillyPfizerActavis (Allergan)BayerNovartisTevaMylanUpsher-SmithFerring PharmaceuticalsKyowa KirinAcerus Pharmaceuticals

Current Market Status, Trends, Types:

GelsInjectionsPatches

Review of Market Growth, Future Prospects, andApplications:

HospitalsClinics

The Regional Segmentation Covers:

North America Region (U.S., Canada, Mexico)

Europe Region (Germany, UK, France, Russia, Italy, Rest of Europe)

Asia-Pacific Region (China, Japan, South Korea, India, Southeast Asia, Rest of Asia-Pacific)

South America Region (Brazil, Argentina, Columbia, Rest of South America)

The Middle East & Africa Region (Saudi Arabia, UAE, Egypt, Nigeria, South Africa, Rest of MEA)

Place An Inquiry Before Investment (Use Corporate Details Only):https://market.us/report/testosterone-replacement-therapy-market/#inquiry

Key Reasons to Purchase:

To achieve insightful analyses of the market and have a thorough understanding of the global Testosterone Replacement Therapy market and its commercial landscape.

Assess the Testosterone Replacement Therapy production processes, major issues, and solutions to mitigate the development risk.

To recognize the most affecting driving and constraining forces in the Testosterone Replacement Therapy market and its impact on the global market.

Discover about the market strategies that are being adopted by leading respective Industries.

To understand the outlook and prospects for the Testosterone Replacement Therapy

Browse More Insight Of This Premium Research Report Enabled with Respective Tables and Figures@https://market.us/report/testosterone-replacement-therapy-market/

People Also Interested In This Research

Global Climbing Helmets Market

Global Hair Serum Market Research Report 2019

Original post:
Global Testosterone Replacement Therapy Market Capacity and Revenue Analysis Till AbbVie,Endo International,Eli lilly - Tech News Today

It's an increasing trend among men.

By Paul Adler

Published: 2017.08.23 02:01

fotolia/davidteamen

As men age, their testosterone levels naturally dip potentially ushering in a host of negative effects including decreased sex drive and muscle mass. Testosterone therapy has risen over the last few decades to fill the gap, but many men wonder when it is time to worry and what the drawbacks of such treatments could be. We asked Michael Werner, MD, the medical director at the Purchase-based Maze Mens Sexual and Reproductive Health when testosterone replacement is truly necessary and what it really entails.

According to Werner, there are a host of symptoms to watch out for when you are worried you may have low levels of the hormone. Men should seek medical help when they [exhibit] some of the symptoms of low testosterone, he says. These include decreased interest in sex, worsening erections, decreased energy, lack of mental focus or fogginess, and difficulty taking off fat and putting on muscle However, Werner insists that the decision of whether or not a man needs testosterone replacement should be made with his doctor.

Werner adds that once the diagnosis that an individuals testosterone levels are low has been made, the patient is then in a place to decide with his doctor which treatment is best for him and his lifestyle. Before seeking treatment, It is also important to note that every patient on testosterone replacement therapy needs to do so under a doctors care and get regular checkups to watch for elevated hematocrit (red blood cell) levels and to make sure his body is not making too much estrogen, explains Werner.

So, what happens once a patient starts receiving the treatment? The first signs the testosterone is doing its job may be increased energy and improved mental acuity, says Werner. In a few months, body fat tends to diminish and men will notice improved exercise performance. According to Werner, it can take six months for men to notice an improvement in erectile function, and nine months for an improvement in libido. He also notes that, for many men, cholesterol levels will improve and overall heart health can get better.

However, the therapy has been linked to serious maladies in the past. The two major concerns that physicians have had were that testosterone replacement therapy could increase the incidence of prostate cancer, or cardiovascular disease, he explains. The vast preponderance of medical evidence does not support these concerns, at all, and the views in the medical community are slowly changing.

As for negative effects, Werner says that some men might notice temporary acne, although most notice no negative effects of being on the treatment. Testosterone replacement therapy can be as inexpensive as $60 for a 3-month vial for self-injection, or hundreds of dollars for implanting pellets which last three months, says Werner. Most insurance companies cover testosterone replacement therapy medication and treatment, when it is medically indicated.

Read more here:
What You Need to Know About Testosterone Replacement - Westchester Magazine